Replies to post #180557 on Biotech Values

[ariadndndough]

CS on aria


¦ ARIA (TP$8, Neutral) – Call on August 6 at 8:30am EST: The primary metric for ARIA is its top-line sales. We forecast US Iclusig sales of $15.9M (up from $8.0M in Q1) vs consensus of $11.1M. The primary focus will be (1) Iclusig re-launch in the US (topline number, patients on drug, line of therapy), (2) plans on restarting trials and additional trials now that partial clinical hold was lifted; (3) plans to move to flat pricing across doses; (4) progress on EU roll-out, including the Pharmacovigilance Risk Assessment Committee (PRAC) delay that was recently announced. We forecast Q2 GAAP EPS of ($0.26) and revenue of $16.0M vs. consensus of ($0.29) and $13.7